Small Molecules Targeting HATs, HDACs, and BRDs in Cancer Therapy

Donglu Wu1,2†, Ye Qiu2,3†, Yunshuang Jiao3, Zhidong Qiu2,3* and Da Liu2,3*

1 School of Clinical Medical, Changchun University of Chinese Medicine, Changchun, China, 2 Key Laboratory of Effective Components of Traditional Chinese Medicine, Changchun, China, 3 School of Pharmacy, Changchun University of Chinese Medicine, Changchun, China

Evidence for research over the past decade shows that epigenetic regulation mechanisms run through the development and prognosis of tumors. Therefore, small molecular compounds targeting epigenetic regulation have become a research hotspot in the development of cancer therapeutic drugs. According to the obvious abnormality of histone acetylation when tumors occur, it suggests that histone acetylation modification plays an important role in the process of tumorigenesis. Currently, as a new potential anticancer therapeutic drugs, many active small molecules that target histone acetylation regulatory enzymes or proteins such as histone deacetylases (HDACs), histone acetyltransferase (HATs) and bromodomains (BRDs) have been developed to restore abnormal histone acetylation levels to normal. In this review, we will focus on summarizing the changes of histone acetylation levels during tumorigenesis, as well as the possible pharmacological mechanisms of small molecules that target histone acetylation in cancer treatment.

Keywords: histone acetylation, cancer, histone deacetylase, histone deacetylase inhibitor, histone acetyltransferase

INTRODUCTION

Histone post-translational modifications (PTMs) directly impact gene transcription by regulating the chromatin architecture (1). Histone acetylation is one of the most well-studied and important PTMs, which mainly affects the status of local chromatin relaxation through changing the distribution of histone acetylation marks in the local chromatin region, thereby regulating gene transcription activation (2). In more detail, the acetylation of histones occurs in the lysine residues on the N-terminal tail of the nucleosome histones composed of H2A, H2B, H3, and H4, and the histone deacetylases (HDACs) and the histone acetyltransferases (HATs) are responsible for adding or removing acetyl groups from the N-terminal tail of the nucleosome histones (3). A large amount of research data demonstrated that histone acetylation widespread in cells is involved in various cellular activities, including genome maintenance, biological processes, DNA damage repair, cell cycle, and apoptosis (4). Once the dynamic balance between acetylation/deacetylation in cells is disrupted, it will cause various diseases, such as Parkinson’s disease, leukemia, and even cancer (5–7). The following will specifically explain the changes in histone acetylation levels during cancer development, and how small molecules as cancer therapeutic drugs target and regulate intracellular acetylation levels.
IMBALANCED HISTONE ACETYLATION LEVELS IN TUMORIGENESIS

Based on the role of histone acetylation in the activation of gene expression, researchers speculated the mechanisms by which histone acetylation participated in and regulated progression of tumorigenesis (8). Multiple histone N-terminal acetylation sites have been identified (Figure 1). And many lysine sites on histones are obviously modulated by acetylation in cancer cells and tumor tissues, suggesting that changes in their acetylation levels are closely related to the occurrence of cancer. Consistent with this argument, it has been confirmed that some HATs or HDACs are abnormally expressed when cancer occurs, resulting in alteration of local chromatin structure by changing the distribution of histone acetylation, ultimately affecting the expression of genes related to tumorigenesis.

It has been reported that the level of acetyl-modification on some histone lysine sites in cancer cells or tissues is obviously abnormal, and the increase or decrease of the modification level varies according to the type of cancer. Regarding H2A, H3K16 acetylknockdown- or Tip60 abrogation-mediated downregulation of H2A cell H2A lysine 5 acetylation (H2AK5ac) decreases HeLa cell colony size, suggesting that this acetylation can regulate cell proliferation (9). Furthermore, Ras-ERK1/2 pathway activation-induced osteosarcoma proliferation and migration co-occurs with downregulated H2BK12ac, a phenotype rescued by HDAC1 knockdown-mediated H2BK12ac restoration (10). Relative to other types of histone acetylation, the H2BK20ac modification preferentially accumulates at promoters of cell type-specific genes, indicating a role in regulating cell-specific functions (11).

Previous data indicate that the acetylation of specific histone lysine sites is associated with the occurrence of certain cancers. Recent research reported that histone H3 acetylation level is correlated with the pathological stage of colorectal cancer, especially with the depth of tumor invasion (12). For instance, downregulation of H3K4ac and H3K9ac has been observed in oral squamous cell carcinoma and ovarian tumors, and the status of acetylation level is tightly correlated with tumor stage, perineural invasion and tumor prognosis (13–15). Part of the reason for the above results may be related to its distribution region on chromatin. Because subsequent studies found that H3K4ac is enriched in the promoter regions of genes which associated with cancer-related phenotypic features, such as the estrogen response and the epithelial-mesenchymal transition (EMT) pathway (16, 17). In head and neck squamous cell carcinoma (HNSCC) cells, H3K4ac modulated by HDAC3 is enriched around the transcription start site of EMT related genes such like GLI1 and SMO, co-overexpression of which promotes HNSCC cell invasion and migration ability (18). In addition to H3K4ac and H3K9ac, high-level of H3K23ac, which is correlated with TRIM24, has been observed in patients with HER2-positive breast cancer, and this correlates with a shorter survival interval (19). Moreover, H3K27 represents a site vulnerable to multiple modification types, including methylation and acetylation, and upregulated H3K27ac in colon cancer and glioma cells is correlated with tumor invasive capability (20, 21). In esophageal squamous cell carcinoma (ESCC), H3K27ac modulated by HDAC3 is enriched around the transcription start site of EMT related genes such like GLI1 and SMO, co-overexpression of which promotes HNSCC cell invasion and migration ability (18). In addition to H3K4ac and H3K9ac, high-level of H3K23ac, which is correlated with TRIM24, has been observed in patients with HER2-positive breast cancer, and this correlates with a shorter survival interval (19). Moreover, H3K27 represents a site vulnerable to multiple modification types, including methylation and acetylation, and upregulated H3K27ac in colon cancer and glioma cells is correlated with tumor invasive capability (20, 21). In esophageal squamous cell carcinoma (ESCC), H3K27ac activates long non coding RNA colon cancer associated transcript-1 (CCAT1), thereby promotes ESCC cells proliferation and migration (22). It is worth noting that some lysine-sites acetylation on histone H3 have been used as biomarkers. For example, H3K18ac and H3K4me2 has been used as biomarker in prostate, pancreatic, lung, and kidney cancers (23, 24). Taken together, unbalanced acetylation level of histone H3 in various cancer tissues or cells suggests that H3 acetylation may be involved in the transcriptional regulation of cancer-related genes.

Regarding H4, modifiable residue K16 is well-studied, and H4K16ac is frequently downregulated in breast cancer, medulloblastoma (25, 26), renal cell carcinoma (RCC), colorectal cancer (CRC) (27, 28), and ovarian cancer (29, 30). However non-small cell lung carcinoma (NSCLC) exhibits
upregulation of H4K16ac and HAT hMOF, resulting in downstream gene expression alterations correlating with tumor size, cell proliferation, and migration (31, 32). In particular, in NSCLC cells hMOF promotes S phase entry by regulating Skp2, thereby stimulates NSCLC tumorigenesis (31). On the other hand, downregulation of H4K5ac observed in acute myeloid leukemia (AML) is associated with shorter survival intervals, and suppressed H4K5ac by MYST2 (Moz-Ybf2/Sas3-Sas2-Tip60) inhibition promotes AML cell growth and colony formation (33). In addition, downregulated H4K12ac consistent with HDAC1, HDAC2, and HDAC6 have been demonstrated in situ in invasive ductal carcinoma (34). Whereas upregulated H3K18ac and H4K12ac are observed in pancreatic cancer (24). A unique role for H4K20ac enriched at transcriptional start sites, co-localizing with NRSF/REST to participate in gene repression has been noted in cancer cells (35).

In summary, biological mechanisms employing acetylated histones are much more diverse than chromatin structure regulation alone. The numerous N-terminal tail lysine residue acetylation sites of H2A, H2B, H3, and H4 allow them to participate in various signaling pathways, and facilitate their multi-faceted roles in cancer cell biology. Indeed, various cancers exhibit a globally dysregulated histone acetylation pattern, correlating with progression, pathological stage, and prognosis. As such, acetylation patterns may have potential as valuable prognostic markers (24).

**HATS, HDACs AND BRDs ACT AS “WRITERS”, “ERASERS,” AND “READERS” RESPECTIVELY**

Biological mechanisms employing acetylated histones are much more diverse than chromatin structure regulation alone. The numerous N-terminal tail lysine residue acetylation sites of H2A, H2B, H3, and H4 allow them to participate in various signaling pathways, and facilitate their multi-faceted roles in cancer cell biology. As mentioned, various cancers exhibit a globally dysregulated histone acetylation pattern, correlating with progression, pathological stage, and prognosis. As such, acetylation patterns may have potential as valuable prognostic markers (24). Noting that the dynamic change and reversible process of the acetyl-group at the N-terminal lysine site of histones can be controlled by certain proteins just like writers, erasers and readers. Cancer-associated abnormal histone acetylation profiles are due to corresponding aberrant expression or catalytic activities of these enzymes. HATs function as “writers”, transferring the acetyl group (-COCH3) from acetyl-CoA (Ac-CoA) to a target histone, whereas HDACs function as “erasers”, removing the acetyl group of a target histone (36, 37). However, whether it is to remove the acetyl group or recruit proteins to a specific acetyl-modified lysine site, the proteins usually have to recognize the acetyl group on a specific protein just like a reader.

Histone-mark readers often recognize marks through the functional domain contained in itself. Based on published literatures, the readers that can recognize histone acetylation are roughly divided into three categories including bromodomain-containing protein (BRD), PHD finger and YEATS domains. Among them, PHD finger and YEATS domain proteins have a wide range of functions. In addition to acetyl-group, they can also recognize methyl-group or other proteins. For example, PHD finger proteins can be able to acquaint acetylated or unacetylated and methylated histones. However, BRD is the only protein group featuring a domain that is able to recognize and bind acetylated histone lysine residues. BRD-containing proteins are widely present in most tissues. According to the sequence or structure similarity, BRDs are divided into eight families exhibiting various activities, including histone modification and chromatin remodeling (Figure 2) (38, 39). For example, one of the most well-known BRD family members, BRD4, accumulates in highly acetylated and transcriptionally prone chromatin regions (including promoters and enhancers) and promotes RNA polymerase II (RNA Pol II) activity, thereby stimulating transcription initiation and transcript elongation. BRD4 is involved in HCC cell growth and invasiveness in vitro, and it is significantly upregulated in HCC tissue (a feature also associated with HCC progression) (40). Such functions are largely dependent on the ability of BRD4 to recognize acetylated proteins (41).

Considering the above description, the addition, removal and recognition of acetyl groups on histones is an indispensable dynamic balance. In other words, acetylation profiles regulated by HATs, HDACs, and BRDs, ultimately impact an abundance of target genes involved in tumorigenesis, thus regulating numerous cellular processes. For example, downregulation of TIP60 in 61% of primary gastric cancer patients is correlated with invasiveness and metastasis (42). Later research data supports this result. Currently, it is generally believed that alteration of HATs or HDACs level is involved in the occurrence and progression of cancer. From the published literature, the decrease of HATs and its enzymatic activity or the excessively high activity of HDACs can directly or indirectly affect the global acetylation level in cells. HAT MOF expression is downregulated in numerous cancers, including RCC, ovarian cancer, gastric cancer, and CRC (33). For additional detail, accumulating data reveals mutation residues on HATs in certain cancer, such as TIP60 in CRC (8). On the contrary, higher level of HDACs such as SIRT1, SIRT2, and SIRT7 were detected in cancer cells (43–45). Given this close relationship, an increasing number of small molecules targeting histone acetylation-regulating proteins are being investigated for their anti-cancer therapeutic potential.

**SMALL MOLECULES TARGETING HATS, HDACs, AND BRDs IN CANCER THERAPY**

**HDAC Inhibitors (HDACis)**

HDACs are enzymes that remove acetyl group on Lys residues of histone proteins, the following four classes of HDACs are recognized: I (HDAC1, 2, 3, and 8), II (A: HDAC4, 5, 7, and 9; B: HDAC6 and 10), III (SIRT1-7), and IV (HDAC11) (Figure 2) (46). Given that the HDACs frequently show higher expression
levels in cancer cells, small molecules targeting HADCs were first investigated. At present, many small molecules have been developed as HDAC inhibitors (HDACis). These HDACis may target different stages of cancer or different signaling pathways, and ultimately achieve the purpose of inhibiting or treating cancer.

So far, five HDACis Vorinostat (SAHA), Belinostat (PXD-101), Panobinostat (LBH589), and chidamide (CS055, HBI-8000) and Romidepsin (FK228) have been approved by the U.S. FDA (Food and Drug Administration) as medicines for treatment of skin T-cell lymphoma (TCL) and peripheral TCL (47, 48). The former three HDACis inhibit class I, II, and IV HDACs, while Romidepsin selectively targets class I (47). As one of the best-studied and pan-HDACi SAHA induces autophagy of chronic lymphocytic leukemia, breast cancer as well as colon cancer cell lines, and the induced autophagy modulates mutant p53 degradation, further affects cancer cell survival (49, 50). In addition to use alone, SAHA induces radio treatment pancreatic cancer cell cycle arrest and apoptosis by targeting RAD51, clarifying the function of SAHA in enhance radiosensitivity (51).

In combination with other anti-cancer drugs, such as oxaliplatin (Eloxatin) and ruxolitinib, SAHA optimally inhibits cancer cell proliferation (52, 53). In addition, an isotretinoin-SAHAs combination for the treatment of neuroblastoma is currently undergoing phase I clinical trials (54).

In addition to SAHA, there are already more than 20 kinds of HDACis in different stages of clinical research, indicating that the research and development of HDACis is very popular and has broad development prospects. Most of the HDACis studied extensively are aimed at the proliferation of tumor cells by targeting cell cycle and apoptosis, growth, and migration capability (55). CG200745, is a pan HDACi, targets HDACs and modulates acetylation, thereby regulates downstream genes including p53, myeloid cell leukemia-1 (Mcl-1) and B-cell lymphoma-extra large (Bcl-xL) (56, 57). In detail, CG200745 inhibits NSCLC cell growth by modulating the profile of H4K16ac at the transcription start site of cell proliferation related genes (58). Moreover, CG200745 (59, 60) enhances the expression of p53 target genes by regulating p53 acetylation, thereby inducing clonogenic cell death (56). In pancreatic cancer, CG200745 elevates the H3 acetylation level and induces the expression of apoptotic proteins, furthermore, CG200745 works better in combination with gemcitabine or erlotinib in suppressing cancer cell proliferation (62). The ability of CG200745 to sensitize tumor cells to existing chemotherapeutic drugs (such as 5-fluorouracil (5-FU), cisplatin, and oxaliplatin) has also been demonstrated (57, 62–64). These data recommend the pan-HDACi CG200745 as a candidate anti-tumor drug or chemotherapy adjuvant, and is currently undergoing the phase I/II clinical trials for pancreatic cancer (62, 65–67).

Although the aforementioned pan-HDACis were approved for clinical application, side effects of these drugs like...
fatigue, nausea, thrombocytopenia, and cardiotoxicity limit its application (67). Thus, selective HDACis that target HDAC6, SIRT1 and SIRT2 have also appeared in recent years. For example, at least six HDAC6-selective inhibitors including SKLB-23bb, ACY1215 (Ricolinostat), ACY241, Tubacin, Tubastatin A, and C1A have been reported (68). In several types of cancer cells such as bladder cancer, malignant melanoma and glioblastoma, HDAC6 is frequently overexpressed (69–71). As a mysterious of HDAC family, HDAC6 possess two catalytic domains and a ubiquitin-binding domain (BUZ), and selective-HDAC6 inhibitors are designed to block the effects of those special functional domains. Selective HDAC6 inhibitors Tubacin and tubastatin A are first developed because they can inhibit the proliferation of glioma and NSCLC by inhibiting autophagy and mediating the Notch1 signaling pathway (72, 73). Further research found that tubastatin A suppresses the ability of colony formation and migration, while in combination with temozolomide, tubastatin A accelerates glioblastoma cells apoptosis, and help glioblastoma multiforme cells overcome ER stress-tolerance (60, 74). Subsequent developed highly selective HDAC6 inhibitors including J22352, ACY1215 (Ricolinostat) and its analogue ACY241, JW-1, ACY1083 etc. come out one after another. Those small molecules present highly effective anti-cancer effects. Among them, ACY1215 and its analogue ACY241 appeared a good anti-tumor effect in synergy with other drugs (59, 61, 75). In particular, ACY1215 has already entered phase II treatment of multiple myeloma (76, 77), and ACY241 has been completed the phase I clinical trial in combination with paclitaxel in solid tumor models (66). In fact, more compounds are still in the experimental research stage. For example, J22352 as a highly HDAC6-selective inhibitor suppresses the proliferation as well as migration of glioblastoma through promoting the proteolysis degradation of HDAC6 and resulting in anti-cancer effect by inhibiting autophagy (71). It is worth noting that HDAC6 is a microtubule-associated deacetylase, which mediates microtubule-dependent cell motility (78, 79). HDAC6 inhibitors JW-1, ACY1083 as well as tubastatin A anchor this characteristic of HDAC6. By inhibiting HDAC6, they can promote the acetylation of α-tubulin (80–82) thereby regulating cancer cell cycle and proliferation (74, 83, 84). HDAC6-selective inhibitor C1A exhibits an additional mechanism of action, inhibiting neuroblastoma and CRC xenograft growth through the modulation of autophagy substrates (85). While MPTG0211 targets HDAC6 thereby accelerates the acetylation of heat shock protein 90 (Hsp90), further inhibits breast cancer metastasis (80). In combination with other anticancer drugs, HDAC6 inhibitor A542 suppresses the proliferation of follicular lymphoma (FL), chronic lymphocytic leukemia (CLL), germinal center diffuse large B-cell lymphoma cells (DLBCL) and CRC by targeting HDAC6 (86, 87). Furthermore, HDAC6 inhibitors such as JOC1, SKLB-23bb, MPTG0413 as well as MPTG0612 show great anticancer activity, whereas the cytoplasm toxic as well as the mechanism are to be further investigated (68, 88–91).

Sirtuins (SIRT1-7) are human homologs of the yeast Sir2 (silent information regulator-2) protein and are divided into four main classes: SIRT1-3 are class I, SIRT4 is class II, SIRT5 is class III and SIRT6-7 are class IV (92). SIRT proteins belong NAD-dependent deacetylases that act as intracellular regulators and are thought to have ADP-ribosyltransferase activity (93). It has been reported that (94–97) SIRT1 and SIRT2 as deacetylases modulate the acetylation of p53, thereby regulating p53 target genes and cancer cell progression (81, 98). JQ-101, which inhibits SIRT1-mediated H4K16 and p53 acetylation, thereby inducing A549 cell senescence and inhibiting tumor growth and invasiveness, similar phenomenon and mechanism has been detected in SIRT1 specific inhibitor EX527 treated glioma cells (82, 99). Moreover, AEM1 and AEM2 also can facilitate p53 acetylation by targeting SIRT2 and further regulating the expression of p53 target genes (e.g., cell cycle regulator p21), thereby sensitizing NSCLC cells to genotoxic stress (100). However, tenovin-6 modulates the mRNA and protein level of p21 in cancer cell lines but through a p53-independent mechanism (101–104).

Recently, with the development of HDAC inhibitors, many newly synthesized, derived derivatives or modified compounds have come out, and pre-clinical experiments have begun. For instance, a novel HDACi (OH-VPA) was developed by modifying a traditional HDACi (VPA), representing a new approach to novel HDACi development. The derivative HDACi is more effective in inhibiting HeLa cell proliferation than its parent molecule (105). In addition, many compounds are still in pre-clinical development, such as abexinostat, AR-42, chidamide, CHR-3996, CI-994, CUDC-101, CUDC-907, entinostat (MS-275), givinostat, MGCD0103, mocetinostat, phenylbutyrate, pivanex, pracinostat, quisinostat, ricolinostat, valproic acid (VPA). Some confer added benefits in combination with other drugs and are undergoing phase I/II clinical trials (Table 1) (62, 65, 94–97, 102–104, 106–109, 112–120, 123–130, 132–135, 139–143, 175, 176).

**Small Molecules Targeting HATs**

This review limits its scope to discussing only HAT inhibitors which have been approved for cancer therapy or commercialization, since the specific mechanisms of HAT modulation-mediated anti-cancer effects are complex and ambiguous (177, 178). It appears that HAT influence during carcinogenesis is context-specific because HATs are able to act as both oncogenes and tumor suppressors (179). The possible reason is that different tumors show mutations in different HAT members, which directly or indirectly affects any steps in the continuous process of tumor progression from tumorigenesis to carcinogenesis and metastasis (180). Based on sequence homology and shared structural features, HATs can be divided into two different classes. One is the Gcn5-related N-acetyltransferases (GNATs) family, including GCN5 and p300/CBP-associated factor (PCAF), that can acetylate lysine residues on histones and non-histone proteins (181). In lung cancer cells, p300 may promote Snail-dependent EMT (epithelial-mesenchymal transition) by acetylating Snail at K187 site.
TABLE 1 | Selective HDAC inhibitors in clinical trials (completed) (from clinicaltrials.gov as of October 2020).

| Compound       | HDAC Selectivity | Clinical Trial Phase and Indication(s)                                                                 | ID# of clinical trial | Reference(s) |
|----------------|------------------|--------------------------------------------------------------------------------------------------------|-----------------------|--------------|
| Abexinostat    | Class I, II      | Phase I for advanced solid tumors.                                                                     | NCT01543763           | (106, 107)   |
|                |                  | Phase I/II for Hodgkin lymphoma.                                                                      | NCT00724984           |              |
|                |                  | Phase I/II for non-Hodgkin lymphoma.                                                                  | NCT04024686           |              |
|                |                  | Phase I/II for chronic lymphocytic leukemia.                                                            | NCT00724984           |              |
|                |                  | Phase I, combined with doxorubicin, for metastatic sarcoma.                                            | NCT01027910           | (108)        |
| ACY241         | HDAC6            | Phase I, in combination with paclitaxel in patients with advanced solid tumors                         | NCT02551185           | (66)         |
|                |                  | Phase I, in combination with pilipilumab and nivalomub to patients with advanced melanoma.            | NCT02957190           | –            |
| AR-42          | Class I, IIb     | Phase I for multiple myeloma and T- and B-cell lymphomas.                                             | NCT01129193           | (109)        |
|                |                  | Phase I, in combination with decitabine in AML in adults and children.                                | NCT01796901           | (110, 111)  |
| Belinostat     | Class I, II, IV  | FDA approved for peripheral T-cell lymphoma.                                                            | NCT00865969           | (94–97, 112,|
|                |                  | Phase I/II for lymphomas and solid tumors.                                                             | NCT01273155           | 113)         |
|                |                  | Phase I, combined with cisplatin and etoposide, for solid lung tumors.                                | NCT00926640           | (114–117),  |
|                |                  | Phase I/II, combined with doxorubicin, for soft tissue sarcomas.                                      | NCT00879800           |              |
|                |                  | Phase I/II, combined with paclitaxel/carboplatin, for carcinoma.                                      | NCT00873119           |              |
|                |                  | Phase I/II, combined with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors.   | NCT01010044           |              |
| Chidamide      | HDAC1-3,10       | Phase II, combined with paclitaxel and carboplatin for advanced NSCLC.                                 | NCT01836679           | (118)        |
| CHR-3996       | Class I          | Phase I for refractory solid tumors.                                                                  | NCT00697879           | (102)        |
| CI-994         | Class I          | Phase II, with or without gemcitabine for pancreatic cancer.                                          | NCT00004861           | (103)        |
|                |                  | Phase II for myeloma.                                                                                  | NCT00005624           | (104)        |
|                |                  | Phase III with or without gemcitabine for advanced NSCLC.                                             | NCT00005093           | (119)        |
| CUDC-101       | Class I, II HDAC/EGFR/HER2 | Phase I for solid tumors.                                      | NCT00728793           | (120)        |
|                |                  | Phase IIb, for advanced head and neck, gastric, breast, liver, and non-small cell lung cancer tumors. | NCT01171924           | (121)        |
|                |                  | Phase I, in combination with concurrent cisplatin and radiation therapy in patients with locally     | NCT01384799           | (122)        |
|                |                  | advanced head and neck cancer.                                                                       |                       |              |
| CUDC-907       | Class I, II      | Phase I for B-cell lymphoma.                                                                          | NCT02674750           | (123)        |
| Entinostat     | Class I          | Phase I, for advanced/relapsed solid tumors.                                                           | NCT02307240           | –            |
| (MS-275)       |                  | Phase II for relapsed and refractory Hodgkin lymphoma.                                                | NCT00866333           | (124, 125), |
|                |                  | Phase II, combined with 5-azacitidine and entinostat, for advanced breast cancer and metastatic CR.   | NCT01105377           | (126, 127), |
|                |                  | Phase I for advanced solid tumors or lymphoma.                                                        | NCT00020579           | (128–130)   |
|                |                  | Phase I/II, combined with avelumab for epithelial ovarian cancer.                                     | NCT02951523           |              |
|                |                  | Phase I, combined with exemestane, for breast cancer.                                                  | NCT02839155           |              |
|                |                  | Phase I/II, combined with azacitidine, for metastatic CRC.                                            | NCT01010537           |              |
|                |                  | Phase I/II, combined with azacitidine, for recurrent advanced NSCLC.                                 | NCT00387485           |              |
| Givinostat     | Class I, II      | Phase II, ITF2357 followed by Mechlorethamine administered to patients with relapsed/                 | NCT00792467           | (131)        |
| (ITF2357)      |                  | refractory Hodgkin’s lymphoma.                                                                       |                       |              |
| Mocetinostat   | Class I, IV      | Phase I for advanced solid tumors or Non-Hodgkin’s Lymphoma.                                          | NCT00329304           | (132)        |
| (MGCD0103)     |                  | Phase I, combined with docetaxel for advanced solid tumors.                                           | NCT00611576           | (133)        |
|                |                  | Phase II for relapsed/refractory lymphoma.                                                            | NCT00350908           | (134, 135)  |
|                |                  | Phase I, combined with gemcitabine, for metastatic leiomyosarcoma.                                    | NCT02303262           | (133)        |
|                |                  | Phase II, for advanced urothelial carcinoma.                                                           | NCT02236195           | (136)        |
|                |                  | Phase I, combined with durvalumab for advanced solid tumors and NSCLC.                               | NCT02836660           | –            |
|                |                  | Phase II for refractory chronic lymphocytic leukemia.                                                 | NCT00431873           | (137)        |
|                |                  | Phase I for leukemia.                                                                                  | NCT00351422           | (138)        |
|                |                  | Phase I/II, in combination with azacitidine for AML.                                                  | NCT00312422           | –            |
|                |                  | Phase I/II, combined with gemcitabine for solid tumors.                                              | NCT00372447           | (133)        |
| Panobinostat   | Class I, II, IV  | FDA approved for multiple myeloma.                                                                    | NCT02568943           | (139–141)   |
|                |                  | Phase II for lymphoma/waldenstrom macroglobulinemia.                                                  | NCT01261247           |              |
|                |                  | Phase I/II, combined with bortezomib, thalidomide, and dexamethasone, for relapsed multiple           | NCT01023308           | (142)        |
|                |                  | myeloma.                                                                                              |                       |              |
| Phenylbutyrate | Class I, II      | Phase I for solid tumors or lymphoma.                                                                  | NCT00002909           | (143)        |
|                |                  | Phase I, combined with azacitidine, for refractory solid tumors.                                      | NCT00005639           | (144)        |
|                |                  | Phase II, for brain tumors in children.                                                                | NCT00006450           | –            |
|                |                  | Phase I, for brain neoplasms and neuroblastoma.                                                       | NCT00015156           | –            |
|                |                  | Phase I, in combination with azacitidine for AML.                                                     | NCT00004871           | (145)        |
| Pivanex        | Class I, II      | Phase II, in combination with docetaxel for advanced NSCLC.                                           | NCT00703385           | (146)        |
| Pracinostat    | Class I, II, IV  | Phase I, treatment alone or with azacitidine for advanced solid tumors.                               | NCT00741234           | (147)        |
| (SB939)        |                  | Phase I, combined with azacitidine for AML.                                                            | NCT01912274           | (148)        |
|                |                  | Phase I, for locally advanced or metastatic solid tumors.                                             | NCT00604296           | –            |

(Continued)
At present, several small molecule compounds targeting p300 have been developed and proved to have anti-cancer effects. For example, (184) Garcinol facilitate HeLa cell apoptosis via inhibiting the HAT activity of P300 and PCAF (185). Similarly, the molecule PU141, a selective CBP/P300 inhibitor, suppresses murine SK-N-SH neuroblastoma xenograft survival (186). Another HAT inhibitor C646 suppresses gastric cancer cell survival and invasive capability through competitively disrupting the interaction between Ac-CoA and CBP/P300 (187, 188). Recently discovered compounds CCT077791 and CCT077792 were also found to target P300 and PCAF, and resulting in the reduction of global acetylation level in colon tumor cell acetylation levels and inhibiting tumor cell proliferation and migration of cholangiocarcinoma (111, 193).

Another HAT family is the MYST superfamily, exhibiting a conserved catalytic MYST domain, and large group membership, including MOZ, Ybf2, Sas2, TIP60, and hMOF (181). The role of MYST family in tumorigenesis is beyond doubt. Based on laboratory research data, Tip60 can harbor substrates including histones and non-histone proteins like p53 and ATM kinase, through which TIP60 plays critical roles in regulating cancer progression such as cell cycle, invasiveness and metastasis in gastric cancer and breast cancer cells (190, 191). Importantly, changes of downregulation of TIP60 is correlated with overall survival of breast cancer patients (42, 192). In addition, by regulating PI3K/AKT pathway, Tip60 suppresses the proliferation and migration of cholangiocarcinoma (111, 193). Given the critical role of TIP60 (a HAT which forms part of the...
TIP60/NuA4 complex) in DNA damage repair, several TIP60 inhibitors have been investigated for their anti-cancer therapeutic potential, including TH1834, NU9056, and 6-alkylsalicylates. Indeed, TH1834 (which blocks the binding site of TIP60) disrupts DNA damage repair to induce breast cancer cell apoptosis (194), and NU9056 both inhibits prostate cancer cell growth and induces apoptosis (195). Similarly, frequent downregulation of MOF has been detected in numerous cancers, including RCC, ovarian cancer, gastric cancer, and CRC (33). Developed MOF inhibitor DC-M01-7 downregulates H4K16ac, inhibiting proliferation of human colon cancer (HCT116) cells (196). Furthermore, through the role of HATs in DNA damage repair, several novel HAT inhibitors sensitize cancer cells to the cytotoxic effects of radiation therapy, suggesting their potential as adjuvants in this context (197, 198). However, there are few reports on selective inhibitors targeting members of this family.

**BRD Inhibitors**

It is common for both histone acetylation and BRDs to become dysregulated in cancer. Current BRD inhibitors (e.g., isoxazoles, purines, quinolinones, tetrahydroquinolines, naphthyridines, and acetylated lysine analogs) exhibit high affinity and specificity for the BET bromine domain (199). Both I-BET 151 and I-BET 762 down-regulate c-Myc transcription, result in inhibition of myeloma cell proliferation (177). Moreover, I-BET 762 suppresses pancreatic cancer cell proliferation (178), and I-BET 762 inhibits breast and lung cancer cell proliferation through cell growth arrest and immune modulation (200). Whereas another BRD inhibitor JO1, by competing with histone acetylated residues, releases BRD4 from chromatin, thereby modulating RNA-Pol II activity to regulate the transcription of key cancer-associated genes (201). In addition, JQ1 decreases the acetylation level and activity of mutant p53, inducing cell growth arrest and subsequent senescence in HNSCC (202). OTX015 (MK-8628, birabresib), one of BRD and extra-terminal domain inhibitors, exhibits antitumor activity in medulloblastoma, B-cell lymphoma, and lung cancer (179, 184, 203). In addition, BET inhibitors such like PLX51107 and NHWD-870 have been identified the activity of tumor proliferation suppression (204, 205). By targeting the interaction of BRDs and acetylated lysine residues on histone, BRD inhibitors modulate chromosome structure and cancer-associated gene expression including c-Myc.

**CONCLUSIONS AND PERSPECTIVES**

Altered histone acetylation—one of the earliest-identified and best-studied epigenetic modifications—is associated with tumorigenesis and tumor progression. Aberrant acetylation profiles are present across various cancer cells, tissues, and types. Given that dynamic histone acetylation/deacetylation is regulated by HDACs, HATs, and BRDs, many small molecules and novel synthesized compounds targeting enzyme catalytic activity or BRD/histone interaction are under investigation for their anti-cancer therapeutic potential (Figure 3). While several agents are already FDA-approved for clinical use, many more are...
undergoing clinical trials, and additional novel agents are being
developed and tested. Indeed, the full clinical therapeutic scope
and commercial value of such agents in the field of oncology is
only just emerging.

AUTHOR CONTRIBUTIONS

ZQ and DL designed the review. DW, YQ, ZQ, YJ, and DL
contributed to manuscript preparation. DW and YQ contributed
equally. All authors contributed to the article and approved the
submitted version.

REFERENCES

1. Rando OJ, Chang HY. Genome-wide views of chromatin structure. Annu Rev
Biochem (2009) 78:245–71. doi: 10.1146/annurev.biochem.78.071107.134639
2. Pal S, Tyler JK. Epigenetics and aging. Sci Adv (2016) 2:e1600584. doi: 10.1126/sciadv.1600584
3. Verdone L, Agricola E, Caserta M, Di Mauro E. Histone acetylation in gene
regulation. Brief Funct Genomic Proteomic (2006) 5:209–21. doi: 10.1093/bfgp/el028
4. Chen H, Tini M, Evans RM. HATs on and beyond chromatin. Curr Opin
Cell Biol (2001) 13:218–24. doi: 10.1016/S0955-0674(00)00200-3
5. Gebremedhin KG, Rademacher DJ. Histone H3 acetylation in the
postmortem Parkinson’s disease primary motor cortex. Neurosci Lett
(2016) 627:121–5. doi: 10.1016/j.neulet.2016.05.060
6. Zhang C, Zhong JF, Stucky A, Chen XL, Press MF, Zhang X. Histone
diacetylase inhibitors (HDACi)s: multitargeted anticancer agents. Biologics
(2013) 7:47–60. doi: 10.2147/BTT.S29965
7. Ververis K, Hiong A, Karagiannis TC, Licciardi PV. Histone deacetylase
inhibitors (HDACi)s: multitargeted anticancer agents. Biologics
(2013) 7:47–60. doi: 10.2147/BTT.S29965
8. Di Cerbo V, Schneider R. Cancers with wrong HATs: the impact of acetylation.
Brief Funct Genomics (2013) 12:231–43. doi: 10.1093/bfgp/el065
9. Tafrov JI, Tafrov ST. Human histone acetyltransferase 1 (Hat1) acetylates
lysine 5 of histone H2A in vivo. Mol Cell Biochem (2014) 392:259–72. doi: 10.1007/s11010-014-2036-0
10. Xu X, Yu H, Xu Y. Ras-ERK1/2 Signaling Promotes The Development Of
Osteosarcoma By Regulating H2BK20ac Through CBP. Cancer Manag Res
(2016) 9:1953–63. doi: 10.2147/CMAR.S219535
11. Kumar V, Rayan NA, Muratani M, Lim S, Elanggovan B, Xin L, et al.
Comprehensive benchmarking reveals H2BK20 acetylation as a distinctive
signature of cell-state-specific enhancers and promoters. Genome Res (2016)
26:612–23. doi: 10.1101/gr.150385.115
12. Hashimoto T, Yamakawa M, Kimura S, Usuba O, Toyono M. Expression of
acetylated and dimethylated histone H3 in colorectal cancer. Dig Surg
(2013) 30:249–58. doi: 10.1159/000351444
13. Chen YW, Kao SY, Wang HJ, Yang MH. Histone modification patterns
 correlate with patient outcome in oral squamous cell carcinoma. Cancer
(2013) 119:4259–67. doi: 10.1002/cncr.28358
14. Zhen L, Gui-lan L, Ping Y, Jin H, Ya-li W. The expression of H3K9Ac, H3K14Ac, and H4K20Dm in
epithelial ovarian tumors and the clinical significance. Int J Gynecol Cancer
(2010) 20:82–6. doi: 10.1111/IGC.0b013e3181ae3efa
15. Mohamed MA, Greif PA, Diamond J, Sharaf O, Maxwell P, Montironi R,
et al. Epigenetic events, remodelling enzymes and their relationship to
chromatin organization in prostatic intraepithelial neoplasia and prostatic
adenocarcinoma. BJU Int (2007) 99:908–15. doi: 10.1111/j.1440-410X.2006.07804.x
16. Iudes G, Dagdemir A, Karsli-Ceppioglu S, Lebert A, Echegut M, Nrollo M,
et al. H3K4 acetylation, H3K9 acetylation and H3K27 methylation in breast
tumor molecular subtypes. Epigenomics (2016) 8:909–24. doi: 10.2217/epi.
2016.0015

FUNDING

This work was supported by National Natural Science
Foundation of China (Grant No. 81572868, 81803680,
81973712, 81903876). Jilin Scientific and Technological
Development Program (Grant No. 20170309005YY).

ACKNOWLEDGMENTS

We would like to thank Editage (www.editage.cn) for English
language editing; Miss Mo Bai for figures editing.
30. Cai M, Hu Z, Liu J, Gao J, Tan M, Zhang D, et al. Expression of hMOF in different ovarian tissues and its effects on ovarian cancer prognosis. Oncol Rep (2015) 33:685–92. doi: 10.3892/or.2014.449
31. Zhao L, Wang DL, Liu Y, Chen S, Sun FL. Histone acetyltransferase hMOF promotes S phase entry and tumorigenesis in lung cancer. Cell Signal (2013) 25:1689–98. doi: 10.1016/j.cellsig.2013.04.006
32. Chen Z, Ye X, Tang N, Shen S, Li Z, Niu X, et al. The histone acetyltransferase hMOF acetylates Nrf2 and regulates anti-drug responses in human non-small cell lung cancer. Br J Pharmacol (2014) 171:3196–211. doi: 10.1111/bph.12661
33. Sauer T, Arteaga MF, Isken F, Rohde C, Hebestreit K, Mikesch JH, et al. MYST2 acetyltransferase expression and Histone H4 Lysine acetylation are suppressed in AML. Exp Hematol (2015) 43:794–802 e4. doi: 10.1016/j.exphem.2015.05.010
34. Suzuki J, Chen YY, Scott GK, Devries S, Chin K, Benz CC, et al. Protein acetylation and histone deacetylation expression associated with malignant breast cancer progression. Clin Cancer Res (2009) 15:3163–71. doi: 10.1158/1078-0432.CCR-08-2319
35. Kaimori JY, Maehara K, Hayashi-Takanaya Y, Harada A, Fukuda M, Yamamoto S, et al. Histone H4 lysine 20 acetylation is associated with gene repression in human cells. Sci Rep (2016) 6:24318. doi: 10.1038/srep24318
36. Iizuka M, Smith MM. Functional consequences of histone modifications. Curr Opin Genet Dev (2005) 15:154–60. doi: 10.1016/S0959-437X(05)00020-0
37. Johnston BW. Histone deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discovery (2002) 1:1287–99. doi: 10.1038/nrd777
38. Duan Y, Guan Y, Qin W, Zhai X, Yu B, Liu H. Targeting Brd4 for cancer therapy: inhibitors and degraders. Med Chem Comm (2018) 9:1777–802. doi: 10.1039/C8MD00198G
39. Zaware N, Zhou MM. Bromodomain biology and drug discovery. Nat Struct Mol Biol (2019) 26:870–9. doi: 10.1038/s41594-019-0309-8
40. Zhang P, Dong Z, Cai J, Zhang C, Shen Z, Ke A, et al. BRD4 promotes tumor growth and epithelial-mesenchymal transition in hepatocellular carcinoma. Int J Immunopathol Pharmacol (2015) 28:36–44. doi: 10.1177/0390419015592070
41. Khoeuery P, Ward Gahlawat A, Petretich M, Michon AM, Simola D, Lam E, et al. BRD4 bimodal binding at promoters and drug-induced displacement at Pol II pause sites associates with I-BET sensitivity. Epigenet Chromatin (2019) 12:39. doi: 10.1186/s13072-019-0268-5
42. Sakuraba K, Yokomizo K, Shirahata A, Goto T, Saito M, Ishibashi K, et al. Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression. Clin Cancer Res (2009) 15:3163–71. doi: 10.1158/1078-0432.CCR-08-2319
43. Singh S, Kumar PU, Thakur S, Kiran S, Sharma S, et al. Expression/ localization patterns of siruins (SIRT1, SIRT2, and SIRT7) during progression of cervical cancer and effects of siruins inhibitors on growth of cervical cancer cells. Tumour Biol Int J Oncodermatol Biol Med (2015) 36:6159–71. doi: 10.1007/s13277-015-3300-y
44. Cha EJ, Noh SJ, Kwon KS, Kim CY, Park BH, Park HS, et al. Expression of DBC1 and SIRT1 is associated with poor prognosis of gastric carcinoma. Clin Cancer Res (2009) 15:4453–9. doi: 10.1158/1078-0432.CCR-08-3329
45. Kim JK, Noh JH, Jung KH, Eun JW, Bae HJ, Kim MG, et al. Sirtuin7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors MiR-125a-5p and MiR-125b. Hepatology (2013) 57:1055–67. doi: 10.1002/hep.26011
46. Evans LW, Ferguson BS. Food Bioactive HDAC Inhibitors in the Epigenetic Regulation of Heart Failure. Nutrients (2018) 10(8):1120. doi: 10.3390/nu10081120
47. Li Y, Seto E. HDACs and HDAC Inhibitors in Cancer Development and Therapy. Cold Spring Harb Perspect Med (2013) 4:e519. doi: 10.1101/cddis.2013.9
48. Lee JH, Mahendran A, Yao Y, Ngo L, Venta-Perez G, Choy ML, et al. Development of a histone deacetylase 6 inhibitor and its biological effects. Proc Natl Acad Sci USA (2013) 110:15704–9. doi: 10.1073/pnas.131393110
49. Li ZY, Zhang C, Zhang Y, Chen L, Chen BD, Li QZ, et al. Novel histone deacetylase inhibitor CG200745, a pan-HDAC inhibitor, in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial. Pediatr Blood Cancer (2018) 65: e27023. doi: 10.1002/pbc.27023
50. Bolden JE, Shi W, Jankowski K, Kan CY, Cluse L, Martin BP, et al. HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses. Cell Death Dis (2013) 4:e519. doi: 10.1038/cddis.2013.9
51. Oh ET, Park MT, Choi BH, Ro S, Choi EK, Jeong SY, et al. Novel histone deacetylase inhibitor CG200745 induces clonogenic cell death by modulating acetylation of p53 in cancer cells. Invest New Drugs (2012) 30:435–42. doi: 10.1007/s10637-010-9568-2
52. Huang JJ, Kim YS, Kim T, Kim MJ, Jeong IG, Lee JH, et al. A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL. Invest New Drugs (2012) 30:1434–42. doi: 10.1007/s10637-011-9718-1
53. Chun SM, Lee JY, Choi J, Lee JH, Kwang J, Kim CS, et al. Epigenetic modulation with HDAC inhibitor CG200745 induces anti-proliferation in non-small cell lung cancer cells. PloS One (2015) 10:e0119379. doi: 10.1371/journal.pone.0119379
54. Lee JH, Mahendran A, Yao Y, Ngo L, Venta-Perez G, Choy ML, et al. Development of a histone deacetylase 6 inhibitor and its biological effects. Proc Natl Acad Sci USA (2013) 110:15704–9. doi: 10.1073/pnas.131393110
55. Lee JH, Mahendran A, Yao Y, Ngo L, Venta-Perez G, Choy ML, et al. Development of a histone deacetylase 6 inhibitor and its biological effects. Proc Natl Acad Sci USA (2013) 110:15704–9. doi: 10.1073/pnas.131393110
56. Park SE, Kim HG, Kim DE, Jung YJ, Kim Y, Jeong SY, et al. Combination treatment with docetaxel and histone deacetylase inhibitors downregulates androgen receptor signaling in castration-resistant prostate cancer. Invest New Drugs (2018) 36:195–205. doi: 10.1007/s10637-017-0529-x
57. Kim KP, Park SJ, Kim JE, Hong YS, Lee JL, Bae KS, et al. First-in-human study of the toxicity, pharmacokinetics, and pharmacodynamics of CG200745, a pan-HDAC inhibitor, in patients with refractory solid malignancies. Invest New Drugs (2015) 33:1048–57. doi: 10.1007/s10637-015-0262-2
58. Huang P, Almeiciga-Pinto I, Jarpe M, van Duzer JH, Mazitschek R, Yang M, et al. Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models. Oncotarget (2018) 9:2694–707. doi: 10.18632/oncotarget.24738
59. Subramanian S, Bates SE, Wright JJ, Espinoza-Delgado I, Piekar RL. Clinical Toxicities of Histone Deacetylase Inhibitors. Pharmaceuticals (Basel) (2010) 3:2751–67. doi: 10.3390/phi3092751
86. Lee DH, Kim GW, Kwon SH. The HDAC6-selective inhibitor is effective against non-Hodgkin lymphoma and synergizes with ibrutinib in follicular lymphoma. Mol Cancer Ther (2018) 17:763–75. doi: 10.1158/1535-7189.MCT-17-0332
87. Zhang X, Yuan Z, Yong S, Salas-Burgos A, Koomen J, et al. HDAC6 modulates cell motility by altering the acetylation level of cortactin. Mol Cell (2007) 27:197–213. doi: 10.1016/j.molcel.2007.05.033
88. Miyake Y, Keusch JJ, Wang L, Saito M, Hess D, Wang X, et al. Structural insights into HDAC6 tubulin deacetylation and its selective inhibition. Biochem Pharmacol (2019) 163:458–71. doi: 10.1016/j.bcp.2019.03.023
89. Yin C, Li P. Growth Suppression of Glioma Cells Using HDAC6 Inhibitor, Tubacin. Open Med (Warsaw Poland) (2018) 13:221–6. doi: 10.1515-med-2018-0034
90. Deskin B, Yin Q, Zhuang Y, Saito S, Shan B, Lasky JA. Inhibition of HDAC6 Attenuates Tumor Growth of Non-Small Cell Lung Cancer. Transl Oncol (2020) 13:135–45. doi: 10.1016/j.tranon.2019.11.001
91. Urdiciain A, Erausquin E, Mele E, Horton J, Varela J, Neisser M, et al. HDAC6 is a microtubule-associated deacetylase. J Biol Chem (2017) 292:14755–68. doi: 10.1074/jbc.M116.766141
92. Amengual JE, Johannet P, Lombardo M, Zullo K, Hoehn D, Bhagat G, et al. Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma. Clin Cancer Res (2015) 21:4663–75. doi: 10.1158/1078-0432.CCR-14-3068
93. Miyake Y, Kusch JJ, Wang L, Saito M, Hess D, Wang X, et al. Structural insights into HDAC6 tubulin deacetylation and its selective inhibition. Nat Chem Biol (2016) 12:748–54. doi: 10.1038/ncchembio.2140
94. Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, et al. HDAC6 is a microtubule-associated deacetylase. Nature (2002) 417:455–8. doi: 10.1038/417455a
95. Tsai HJ, Pan SL, Liou JP, Yang CR. Anti-metastatic activity of MTP0G211, a novel HDAC6 inhibitor, in human breast cancer cells in vitro and in vivo. Biochim Biophys Acta Mol Cell Res (2019) 1866:992–1003. doi: 10.1016/j.jbmbarc.2019.03.003
96. Lau AW, Liu P, Inuzuka H, Gao D. SIRT1 phosphorylation by AMP-activated protein kinase regulates p53 acetylation. Mol Cancer Res (2014) 4:245–55.
97. Zhou L, Qi J, Chao CY, Zhang Q, Porco JA Jr., Faller DV, et al. Identification of a novel polypropenylacylphosphoglycerolincorrelated SIRT1 inhibitor with cancerspecific anti-proliferative and invasion-suppressing activities. Int J Oncol (2014) 45:2128–36. doi: 10.3892/ijo.2014.2639
98. Ho YH, Wang KJ, Hung PY, Cheng YS, Liu JR, Fung ST, et al. A phase I/II Exploratory Study of PXD-101 (Belinostat) Followed by Zevalin in Patients with Relapsed Aggressive High-Risk Lymphoma. Oncology (2017) 93:401–5. doi: 10.1159/000479230
99. Bailey H, McPherson JP, Bailey EB, Werner TL, Gupta S, Batten J, et al. A phase I study to determine the pharmacokinetics and urinary excretion of belinostat and metabolites in patients with advanced solid tumors. Cancer Chemother Pharmacol (2016) 78:1059–71. doi: 10.1007/s00280-016-3167-7
100. Hoffmann G, Breitenbacher F, Schuler M, Ehrenhofer-Murray AE. A novel sirtuin 2 (SIRT2) inhibitor with p53-dependent pro-apoptotic activity in non-small cell lung cancer. J Biol Chem (2014) 289:5208–16. doi: 10.1074/jbc.M113.487736
101. McCarthy AR, Sachweh MC, Campbell J, Drummond CJ, van Leeuwen IM, Higgins M, Campbell J, McCarthy AR, Sachweh MC, Navarro AM, et al. Modulation of p53 C-terminal acetylation by mdm2, p14ARF, and cytoplasmic SirT2. Mol Cancer Ther (2013) 12:471–80. doi: 10.1159/000479230
109. Sborov DW, Terriou L, Foisser I, Bachy E, Varga A, Kloos I, et al. Phase 1 study of the oral histone deacetylase inhibitor abexinostat in combination with standard hypofractionated radiotherapy in advanced solid tumors. Oncotarget (2017) 8:56199–209. doi: 10.18632/oncotarget.14147

107. Morschhauser F, Terriou L, Balasubramanian S, Rutynski JE, Harmon DC, George S, et al. Phase I study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma. Cancer (2015) 121:1223–30. doi: 10.11000/cncr.29175

109. Choy E, Flamand Y, Balasubramanian S, Butrynski JE, Harmon DC, George S, et al. A phase 1 dose-escalation study of the oral histone deacetylase inhibitor vorinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukemia. Invest New Drugs (2015) 33:423–31. doi: 10.1007/s10637-015-0206-x

110. Pili R, Quinn DI, Hammers HI, Monk P, George S, Dorff TB, et al. Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#870). Cancer Res An Off J Am Assoc Cancer Res (2017) 77:2199–208. doi: 10.1158/1078-0432.CCR-17-1718

108. Mims A, Walker AR, Huang X, Sun X, Wang H, Santhanam R, et al. Increased radiation response with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC). Anti-cancer Drugs (2015) 8:35326. doi: 10.1046/j.1000-402.2005.02601.x

107. OConnor OA, Horwitz S, Masszi T, Van Hoof A, Brown P, Doorduijn J, et al. Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BILEF (CLIN-19) Study. J Clin Oncol Off J Am Soc Clin Oncol (2015) 33:2492–9. doi: 10.1200/JCO.2014.59.2782

112. Yu X, Wang L, Lin L, Han X, Dou G, Meng Z, et al. A phase I study of romidepsin, gemcitabine, dexamethasone and paclitaxel in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol Off J Am Soc Clin Oncol (2011) 29:2052–9. doi: 10.1200/JCO.2010.32.4467

113. Giaccone G, Rajan A, Berman A, Kelly RJ, Szabo E, Lopez-Chavez A, et al. Combination Epigenetic Therapy in Advanced Breast Cancer With 5-Azacytidine and Entinostat: A Phase II National Cancer Institute/Stand Up To Cancer Study. Clin Cancer Res An Off J Am Soc Clin Oncol (2017) 23:2691–701. doi: 10.1158/1078-0432.CCR-16-1729

111. Liva SG, Coss CC, Wang J, Blum W, Klisovic R, Bhaptagar N, et al. Phase I study of AR-42 and debacitine in acute myeloid leukemia. Leuk Lymphoma (2020) 61:1484–92. doi: 10.1080/10428194.2020.1719095

114. Balasubramaniam S, Redon CE, Peer CJ, Blyra C, Lee MJ, Trepel JB, et al. Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung. Anti-cancer Drugs (2018) 29:457–65. doi: 10.1097/CAD.0000000000000596

115. Vitfell-Rasmussen J, Iudson J, Salwaf A, Jones RL, Rosser PB, Lind-Hansen M, et al. A Phase I/II Clinical Trial of Belinostat (PXD101) in Combination with Doxorubicin in Patients with Soft Tissue Sarcomas. Sarcoma (2016) 2016:2090271. doi: 10.1155/2016/2090271

116. Hainsworth JD, Daugaard G, Lesimple T, Hubner G, Greco FA, Stahl M, et al. Paclitaxel/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial. Cancer (2015) 121:1654–61. doi: 10.11000/cancer.32929

117. Thomas A, Rajan A, Szabo E, Tomita C, Carter CA, Scepura B, et al. A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational study. Clin Cancer Res An Off J Am Assoc Cancer Res (2014) 20:5392–402. doi: 10.1158/1078-0432.CCR-14-0968

118. Wu et al. Small Molecules Targeting Histone Acetylation

119. Hu X, Wang L, Lin L, Han X, Dou G, Meng Z, et al. A phase I trial of an oral subtype-selective histone deacetylase inhibitor, chidamide, in combination with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer. Chin J Cancer Res (2016) 28:444–51. doi: 10.11217/j.issn.1000-9604.2016.04.08

120. Chidambaram A, Sundararaju K, Chidambaram RK, Subbiah R, Jayaraj JM, Muthusamy K, et al. Design, synthesis, and characterization of ω, β-unaturated carboxylic acid, and its urea based derivatives that explores novel epigenetic modulators in human non-small cell lung cancer A549 cell line. J Cell Physiol (2018) 233:5293–309. doi: 10.1002/jcp.26333

121. Sborov DW,Terriou L, Foisser I, Bachy E, Varga A, Kloos I, et al. Phase I study of oral vorinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukemia. Invest New Drugs (2015) 33:423–31. doi: 10.1007/s10637-015-0206-x

122. Shimizu T, LoRusso PM, Papadopoulos KP, Patnaik A, Beeram M, Smith LS, et al. Phase I first-in-human study of CUDC-101, a multtargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumors. Cancer Res An Off J Am Assoc Cancer Res (2014) 20:5032–40. doi: 10.1158/1078-0432.CCR-14-0570

123. Wang J, Pursell NW, Samson ME, Atoyan R, Ma AW, Selmi A, et al. Potential advantages of CUDC-101, a multtargeted HDAC, EGFR, and HER2 inhibitor, in treating drug resistance and preventing cancer cell migration and invasion. Mol Ther Cancer 2013) 12:925–36. doi: 10.1158/1535-7163.MCT-12-1045

124. Galloway TJ, Wirth LJ, Colevas AD, Gilbert J, Baume JN, Saba NF, et al. A Phase I Study of CUDC-101, a Multtargeted Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma. Clin Cancer Res (2015) 21:1566–73. doi: 10.1158/1078-0432.CCR-14-2820

125. Oki Y, Kelly KR, Flinn I, Patel MR, Gharavi R, Ma A, et al. CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase 1 trial. Haematologica (2017) 102:1923–30. doi: 10.3324/haematol.2017.172882
136. Grivas P, Mortzavai A, Picus J, Hahn NM, Milowski MI, Hart LL, et al. Mocetinostat in patients with previously treated, locally advanced/metastatic urothelial carcinoma, inactivating alterons. J Clin Oncol (2019) 125:533–40. doi: 10.1002/jco.263187

137. Blum KA, Advani A, Fernandez L, Van Der Jagt R, Brandwein J, Kambhampati S, et al. Phase II study of the histone deacetylase inhibitor MGD0103 in patients with previously treated chronic lymphocytic leukemia. Br J Haematol (2009) 147:507–14. doi: 10.1111/j.1365-2457.2009.07881.x

138. Garcia-Manero G, Assouline S, Cortes J, Estrov Z, Kantarjian H, Yang Y, et al. Phase I study of the oral isotype specific histone deacetylase inhibitor MGD0103 in leukemia. Blood (2008) 112:981–9. doi: 10.1182/blood-2007-11-105873

139. Richardson PG, Laubach JP, Lonal S, Moreau P, Yoon SS, Hungria VT, et al. Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or refractory multiple myeloma. Expert Rev Anticancer Ther (2015) 15:73–47. doi: 10.1586/14737442.2015.1047770

140. Yones A, Sureda A, Ben Yehuda D, Zinzani PL, Ong TC, Prince HM, et al. Panobinostat in patients with relapsed/refractory Hodgkin’s lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol Off J Am Soc Clin Oncol (2012) 30:2197–203. doi: 10.1200/JCO.2011.38.1350

141. Duvic M, Dummer R, Becker JC, Poualhon N, Ortiz Romero P, Grazia Bernengo M, et al. Panobinostat activity in both bexarotene-exposed and naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial (Oxford, England ; 1990). Eur J (2013) 49:386–94. doi: 10.1016/j.ejca.2012.12.012

142. Popat R, Brown SR, Flanagan L, Hall A, Gregory W, Kishore B, et al. Extended activity, in patients with advanced solid tumors. J Clin Oncol (2015) 33:969 –78. doi: 10.1409/14737442.2015.1117611

143. Maslak P, Chanel S, Camacho LH, Soignet S, Pandol SK, et al. Pracinostat plus azacitidine in older patients with newly diagnosed-refractory multiple myeloma: a multicenter phase 1b trial. Lancet Oncol (2016) 17:1569–78. doi: 10.1016/S1470-2045(16)30375-8

144. Iannitti T, Palmieri B. Clinical and experimental applications of sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or in leukemia. Curr Opin Oncol (2009) 15:6241 –49. doi: 10.1097/SJO.0b013e32832e25f7

145. Venugopal B, Baird R, Kristeleit RS, Plummer R, Cowan R, Stewart A, et al. A phase I/II study targeting angiogenesis in patients with relapsed or refractory peripheral T-cell lymphoma: a phase I/II and pharmacokinetics study. Int J Hematol (2015) 100:6655–65. doi: 10.1007/s11285-015-2286-1

146. Vogl DT, Raje N, Jagannath S, Richardson P, Hari P, Orlovsky R, et al. Panobinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma. Clin Cancer Res (2017) 23:3307–15. doi: 10.1158/1078-0433.CCR-16-2526

147. Caponigro F, Di Gennaro E, Ionna F, Longo F, Aversa C, Pavone E, et al. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck–CHANCE trial. BMC Cancer (2016) 16:918. doi: 10.1186/s12885-016-2957-y

148. Liu AM, Fu S, Falchook GS, Ng CS, Wheler JJ, Abdelrahim M, et al. Phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Haematologica (2018) 103:416–8. doi: 10.3324/haematol.2018.187617

149. Fujita M, Murakami S, Swami U, Tanaka M, Smolder M, Smith B, et al. A Phase I/II Study Targeting Angiogenesis Using Bevacizumab Combined with Chemotherapy and a Histone Deacetylase Inhibitor (Valproic Acid) in Advanced Sarcomas. Cancers (2018) 10(2):35. doi: 10.3390/cancers10020053

150. Shrikhande N, Chodosh LA, Bonecchi R, Aversa C, Pavone E, et al. Inhibitory effect alone or in combination with retinoids on proliferation of simple and high-yield synthesis of suberoylanilide hydroxamic acid and its histone deacetylase inhibitor (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RABMs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts. Bioorg Med Chem (2008) 16:3352–60. doi: 10.1016/j.bmc.2007.12.007

151. Popat R, Brown SR, Flanagan L, Hall A, Gregory W, Kishore B, et al. Extended follow-up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (MUK six open label, multi-centre phase I/II Clinical Trial). Br J Haematol (2018) 183(5):573–8. doi: 10.1111/bjh.15551

152. Gracina-Manero G, Abaza Y, Takahashi K, Medeiros BC, Arellano M, Khaled SK, et al. Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study. Blood Adv (2019) 3:508–18. doi: 10.1182/bloodadvances2018027409

153. Muller P, Facon T, Touzeau C, Benoubker L, Delain M, Badamo-Dotzi J, et al. Quisinostat, a novel hydroxamic acid histone deacetylase inhibitor, in patients with previously treated stage IB-IVA mycosis fungoides/Sézary syndrome. Br J Dermatol (2016) 175:80–8. doi: 10.1111/ bjd.14427

154. Eckschlagert T, Pich J, Stiborova M, Brabeta J. Histone Deacetylase Inhibitors as Anticancer Drugs. Int J Mol Sci (2017) 18(7):1444. doi: 10.3390/ijms18071444

155. Popat R, Brown SR, Flanagan L, Hall A, Gregory W, Kishore B, et al. Phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Haematologica (2018) 103:416–8. doi: 10.3324/haematol.2018.187617

156. Venugopal B, Baird R, Kristeleit RS, Plummer R, Cowan R, Stewart A, et al. A phase I/II study targeting angiogenesis using bevacizumab combined with chemotherapy and a histone deacetylase inhibitor (valproic acid) in advanced sarcomas. Cancers (2018) 10(2):35. doi: 10.3390/cancers10020053

157. Gediya LK, Chopra P, Purushottamachar P, Njar VC. Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CL-994) and inhibitory effects of HDIs alone or in combination with RABMs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts. Bioorg Med Chem (2008) 16:3352–60. doi: 10.1016/j.bmc.2007.12.007
